Case Report: Dramatic Response to Crizotinib in a Patient With Non-Small Cell Lung Cancer Positive for a Novel ARL1-MET Fusion

It is imperative to know the status of oncogenic drivers in patients with non-small cell lung cancer (NSCLC). Compared with ALK and ROS1 fusion, MET fusion is relatively rare in NSCLC. In this case, we report the case of a female patient with NSCLC positive for a novel ARL1-MET fusion. The patient a...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Qing, Kong, Lingping, Zhong, Diansheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883050/
https://www.ncbi.nlm.nih.gov/pubmed/35237515
http://dx.doi.org/10.3389/fonc.2022.804330
_version_ 1784659842904883200
author Ma, Qing
Kong, Lingping
Zhong, Diansheng
author_facet Ma, Qing
Kong, Lingping
Zhong, Diansheng
author_sort Ma, Qing
collection PubMed
description It is imperative to know the status of oncogenic drivers in patients with non-small cell lung cancer (NSCLC). Compared with ALK and ROS1 fusion, MET fusion is relatively rare in NSCLC. In this case, we report the case of a female patient with NSCLC positive for a novel ARL1-MET fusion. The patient achieved about a 5-month progression-free survival (PFS) after receiving crizotinib for unresectable right lung malignancies. To the best of our knowledge, this case provides the first clinical evidence that the novel ARL1-MET fusion might be an actionable mutation in NSCLC.
format Online
Article
Text
id pubmed-8883050
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88830502022-03-01 Case Report: Dramatic Response to Crizotinib in a Patient With Non-Small Cell Lung Cancer Positive for a Novel ARL1-MET Fusion Ma, Qing Kong, Lingping Zhong, Diansheng Front Oncol Oncology It is imperative to know the status of oncogenic drivers in patients with non-small cell lung cancer (NSCLC). Compared with ALK and ROS1 fusion, MET fusion is relatively rare in NSCLC. In this case, we report the case of a female patient with NSCLC positive for a novel ARL1-MET fusion. The patient achieved about a 5-month progression-free survival (PFS) after receiving crizotinib for unresectable right lung malignancies. To the best of our knowledge, this case provides the first clinical evidence that the novel ARL1-MET fusion might be an actionable mutation in NSCLC. Frontiers Media S.A. 2022-02-14 /pmc/articles/PMC8883050/ /pubmed/35237515 http://dx.doi.org/10.3389/fonc.2022.804330 Text en Copyright © 2022 Ma, Kong and Zhong https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Ma, Qing
Kong, Lingping
Zhong, Diansheng
Case Report: Dramatic Response to Crizotinib in a Patient With Non-Small Cell Lung Cancer Positive for a Novel ARL1-MET Fusion
title Case Report: Dramatic Response to Crizotinib in a Patient With Non-Small Cell Lung Cancer Positive for a Novel ARL1-MET Fusion
title_full Case Report: Dramatic Response to Crizotinib in a Patient With Non-Small Cell Lung Cancer Positive for a Novel ARL1-MET Fusion
title_fullStr Case Report: Dramatic Response to Crizotinib in a Patient With Non-Small Cell Lung Cancer Positive for a Novel ARL1-MET Fusion
title_full_unstemmed Case Report: Dramatic Response to Crizotinib in a Patient With Non-Small Cell Lung Cancer Positive for a Novel ARL1-MET Fusion
title_short Case Report: Dramatic Response to Crizotinib in a Patient With Non-Small Cell Lung Cancer Positive for a Novel ARL1-MET Fusion
title_sort case report: dramatic response to crizotinib in a patient with non-small cell lung cancer positive for a novel arl1-met fusion
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883050/
https://www.ncbi.nlm.nih.gov/pubmed/35237515
http://dx.doi.org/10.3389/fonc.2022.804330
work_keys_str_mv AT maqing casereportdramaticresponsetocrizotinibinapatientwithnonsmallcelllungcancerpositiveforanovelarl1metfusion
AT konglingping casereportdramaticresponsetocrizotinibinapatientwithnonsmallcelllungcancerpositiveforanovelarl1metfusion
AT zhongdiansheng casereportdramaticresponsetocrizotinibinapatientwithnonsmallcelllungcancerpositiveforanovelarl1metfusion

Ejemplares similares